Jeffrey Alder

412 total citations
17 papers, 301 citations indexed

About

Jeffrey Alder is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Jeffrey Alder has authored 17 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 7 papers in Epidemiology and 6 papers in Clinical Biochemistry. Recurrent topics in Jeffrey Alder's work include Bacterial Identification and Susceptibility Testing (6 papers), Antimicrobial Resistance in Staphylococcus (5 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Jeffrey Alder is often cited by papers focused on Bacterial Identification and Susceptibility Testing (6 papers), Antimicrobial Resistance in Staphylococcus (5 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Jeffrey Alder collaborates with scholars based in United States, Spain and France. Jeffrey Alder's co-authors include Jared Silverman, Barry I. Eisenstein, Jacob J. Clement, Judith N. Steenbergen, Jennifer M Streit, Grace M. Thorne, Ronald N. Jones, Michael J. Mitten, Kennan C. Marsh and S. Ken Tanaka and has published in prestigious journals such as Journal of Nutrition, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Jeffrey Alder

17 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Alder United States 9 137 121 78 65 61 17 301
Lynn McCloskey United States 7 117 0.9× 139 1.1× 53 0.7× 65 1.0× 67 1.1× 10 355
J E Flokowitsch United States 8 308 2.2× 174 1.4× 97 1.2× 84 1.3× 53 0.9× 10 453
Nicolas Blondiaux France 13 152 1.1× 114 0.9× 115 1.5× 79 1.2× 28 0.5× 24 443
G. C. Kedar Spain 7 164 1.2× 153 1.3× 35 0.4× 33 0.5× 37 0.6× 8 281
S T Selepak United States 8 112 0.8× 81 0.7× 71 0.9× 72 1.1× 119 2.0× 10 392
Danielle M. McGrath United States 4 200 1.5× 121 1.0× 49 0.6× 34 0.5× 21 0.3× 5 353
Minoru Yonezawa Japan 10 120 0.9× 139 1.1× 123 1.6× 164 2.5× 27 0.4× 16 400
Quang Dam United States 5 134 1.0× 166 1.4× 56 0.7× 68 1.0× 26 0.4× 8 408
S. Ken Tanaka United States 9 90 0.7× 98 0.8× 117 1.5× 47 0.7× 42 0.7× 11 359
Mélanie Roch Switzerland 10 153 1.1× 134 1.1× 43 0.6× 71 1.1× 13 0.2× 18 322

Countries citing papers authored by Jeffrey Alder

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Alder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Alder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Alder more than expected).

Fields of papers citing papers by Jeffrey Alder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Alder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Alder. The network helps show where Jeffrey Alder may publish in the future.

Co-authorship network of co-authors of Jeffrey Alder

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Alder. A scholar is included among the top collaborators of Jeffrey Alder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Alder. Jeffrey Alder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Waele, Jan J. De, José M. Tellado, Günter Weiß, et al.. (2014). Efficacy and Safety of Moxifloxacin in Hospitalized Patients with Secondary Peritonitis: Pooled Analysis of Four Randomized Phase III Trials. Surgical Infections. 15(5). 567–575. 6 indexed citations
3.
Alder, Jeffrey. (2008). The Use of Daptomycin for Staphylococcus Aureus Infections in Critical Care Medicine. Critical Care Clinics. 24(2). 349–363. 8 indexed citations
4.
Streit, Jennifer M, Judith N. Steenbergen, Grace M. Thorne, Jeffrey Alder, & Ronald N. Jones. (2005). Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. Journal of Antimicrobial Chemotherapy. 55(4). 574–578. 28 indexed citations
5.
Alder, Jeffrey. (2005). Daptomycin, a new drug class for the treatment of Gram-positiveinfections. Drugs of today. 41(2). 81–81. 45 indexed citations
6.
Alder, Jeffrey & Barry I. Eisenstein. (2004). The advance of bacterididal drugs in the treatment of infection. Current Infectious Disease Reports. 6(4). 251–253. 33 indexed citations
7.
Alder, Jeffrey, et al.. (2003). In Vitro Bactericidal Activities of Daptomycin against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by Inhibition of Lipoteichoic Acid Biosynthesis. Antimicrobial Agents and Chemotherapy. 47(8). 2682–2684. 76 indexed citations
8.
Klein, Larry L., Leping Li, Hui-Ju Chen, et al.. (2000). Total synthesis and antifungal evaluation of cyclic aminohexapeptides. Bioorganic & Medicinal Chemistry. 8(7). 1677–1696. 33 indexed citations
9.
Ewing, Patty J., et al.. (1998). In Vivo Efficacy of ABT-255 against Drug-Sensitive and -Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy. 42(10). 2674–2677. 16 indexed citations
10.
Alder, Jeffrey. (1997). Determining the Therapeutic Potential of Experimental Antibacterial Agents: The Use of Animal Models. Current Pharmaceutical Design. 3(2). 143–158. 6 indexed citations
11.
Meulbroek, Jonathan A., Anatol Oleksijew, S. Ken Tanaka, & Jeffrey Alder. (1996). Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis. Journal of Antimicrobial Chemotherapy. 38(4). 641–653. 6 indexed citations
12.
Alder, Jeffrey, Hui Yu, & Jacob J. Clement. (1995). Efficacy of AZT therapy in reducing p24 antigen burden in a modified SCID mouse model of HIV infection. Antiviral Research. 27(1-2). 85–97. 7 indexed citations
13.
Alder, Jeffrey, et al.. (1994). Enteral Formula Composition Does Not Affect Response to Lethal Infectious Challenge in Mice. Journal of Nutrition. 124(11). 2156–2162. 3 indexed citations
14.
Alder, Jeffrey, Michael J. Mitten, Lisa E. Hernandez, et al.. (1994). Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole. Journal of Antimicrobial Chemotherapy. 33(2). 253–263. 8 indexed citations
15.
Alder, Jeffrey, et al.. (1994). Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. Antiviral Research. 23(2). 93–105. 16 indexed citations
16.
Alder, Jeffrey & Jacob J. Clement. (1993). Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model. Journal of Antimicrobial Chemotherapy. 31(2). 303–311. 6 indexed citations
17.
Alder, Jeffrey & Julius P. Kreier. (1989). Immune complexes in serum of rats during infection withPlasmodium berghei. Parasitology Research. 76(2). 119–126. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lynn McCloskey Breakdown of academic impact, for papers by J E Flokowitsch Breakdown of academic impact, for papers by Nicolas Blondiaux Breakdown of academic impact, for papers by G. C. Kedar Breakdown of academic impact, for papers by S T Selepak Breakdown of academic impact, for papers by Danielle M. McGrath Breakdown of academic impact, for papers by Minoru Yonezawa Breakdown of academic impact, for papers by Quang Dam Breakdown of academic impact, for papers by S. Ken Tanaka Breakdown of academic impact, for papers by Mélanie Roch
Rankless by CCL
2026